About Celgene (NASDAQ:CELG)
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.
Industry, Sector and Symbol
Trailing P/E Ratio13.89
Forward P/E Ratio12.40
Sales & Book Value
Annual Sales$13.00 billion
Price / Sales5.51
Cash Flow$7.62 per share
Price / Cash12.50
Book Value$8.79 per share
Price / Book10.84
Net Income$2.94 billion
Return on Equity67.50%
Return on Assets18.33%
Celgene (NASDAQ:CELG) Frequently Asked Questions
What is Celgene's stock symbol?
Celgene trades on the NASDAQ under the ticker symbol "CELG."
When did Celgene's stock split? How did Celgene's stock split work?
Celgene's stock split on Thursday, June 26th 2014. The 2-1 split was announced on Thursday, June 19th 2014. The newly minted shares were distributed to shareholders after the market closes on Wednesday, June 25th 2014. An investor that had 100 shares of Celgene stock prior to the split would have 200 shares after the split.
How will Celgene's stock buyback program work?
Celgene declared that its Board of Directors has approved a stock buyback plan on Wednesday, February 14th 2018, which permits the company to repurchase $5,000,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to buy shares of its stock through open market purchases. Shares repurchase plans are often a sign that the company's management believes its stock is undervalued.
How were Celgene's earnings last quarter?
Celgene Co. (NASDAQ:CELG) posted its earnings results on Thursday, January, 25th. The biopharmaceutical company reported $1.87 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.78 by $0.09. The biopharmaceutical company had revenue of $3.48 billion for the quarter, compared to the consensus estimate of $3.46 billion. Celgene had a return on equity of 67.50% and a net margin of 22.38%. The company's revenue for the quarter was up 16.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.61 earnings per share. View Celgene's Earnings History.
When will Celgene make its next earnings announcement?
What guidance has Celgene issued on next quarter's earnings?
Celgene issued an update on its FY18 earnings guidance on Thursday, January, 25th. The company provided earnings per share guidance of $8.70-8.90 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $8.65. The company issued revenue guidance of $14.4-14.8 billion, compared to the consensus revenue estimate of $14.77 billion.
Where is Celgene's stock going? Where will Celgene's stock price be in 2018?
30 Wall Street analysts have issued 1-year price targets for Celgene's shares. Their forecasts range from $91.00 to $166.00. On average, they anticipate Celgene's share price to reach $130.36 in the next year. View Analyst Ratings for Celgene.
What are Wall Street analysts saying about Celgene stock?
Here are some recent quotes from research analysts about Celgene stock:
- 1. Cann analysts commented, "Celgene announced today that John Weiland has been elected to its board of directors. Mr. Weiland was most recently President and Chief Operating Officer of C.R. Bard, Inc. Prior to this role, Mr. Weiland held the position of Group President of Bard and had global responsibility for Bard Medical Division, Bard Urological Division, Davol Inc., Bard Endoscopic Technologies Division and Bard’s Worldwide Manufacturing Operations. We believe Mr. Weiland will bring significant commercial and operational experience to the Celgene Board." (2/15/2018)
- 2. According to Zacks Investment Research, "Celgene’s fourth-quarter results were encouraging as the company beat on both sales and earnings. While Revlimid sales were impressive yet again, Abraxane sales declined in the United States. Sales of Otezla have picked up too after a slowdown in the third quarter. However, Celgene is highly dependent on Revlimid. Celgene’s stock has underperformed the industry in the last six months. Celgene suffered a setback as the label expansion study on lead drug Revlimid failed in phase III. The stock was hit earlier after a phase III trial, REVOLVE, (CD-002) on pipeline candidate GED-0301 in Crohn’s disease and the extension trial, SUSTAIN (CD-004) was discontinued. The threat of generic competition is also looming large on Revlimid forcing Celgene to look for acquisitions and the announcement of Juno’s acquisition was on the same track. However, the Juno acquisition comes with its own set of risks." (1/31/2018)
- 3. Cantor Fitzgerald analysts commented, "CELG’s current CEO, Mark Alles, will assume the role of Chairman of the Board, following the retirement of current COB Robert Hugin, effective February 5th, which follows his departure as President in early 2016." (1/29/2018)
Are investors shorting Celgene?
Celgene saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 14,380,412 shares, an increase of 10.3% from the January 12th total of 13,038,301 shares. Based on an average daily volume of 9,042,197 shares, the days-to-cover ratio is currently 1.6 days. Approximately 1.8% of the shares of the company are short sold.
Who are some of Celgene's key competitors?
Some companies that are related to Celgene include Amgen (AMGN), Bristol-Myers Squibb (BMY), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), Sanofi (SNY), GlaxoSmithKline (GSK), Eli Lilly and (LLY), AstraZeneca (AZN), GlaxoSmithKline (GSK), AstraZeneca (AZN), Beximco Pharmaceuticals (BXP), Shire (SHPG), Shire (SHP), Teva Pharmaceutical Industries (TEVA), Valeant Pharmaceuticals Intl (VRX), Catalent (CTLT), Dr.Reddy's Laboratories (RDY) and Patheon (PTHN).
Who are Celgene's key executives?
Celgene's management team includes the folowing people:
- Mark J. Alles, Chairman of the Board, Chief Executive Officer (Age 58)
- Scott A. Smith, President, Chief Operating Officer (Age 55)
- Peter N. Kellogg, Chief Financial Officer, Executive Vice President (Age 61)
- Terrie Curran, President, Global Inflammation & Immunology Franchise (Age 48)
- Michael F. Pehl, President, Hematology & Oncology (Age 52)
- Rupert J Vessey, President - Research and Early Development (Age 52)
- Gerald F. Masoudi, Executive Vice President, General Counsel and Corporate Secretary (Age 49)
- Michael D. Casey, Lead Independent Director (Age 71)
- Michael W. Bonney, Director (Age 59)
- Julia A. Haller M.D., Director (Age 62)
Who owns Celgene stock?
Celgene's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.26%), Franklin Resources Inc. (1.38%), Jennison Associates LLC (1.25%), Bank of New York Mellon Corp (1.17%), Geode Capital Management LLC (1.10%) and Clearbridge Investments LLC (0.84%). Company insiders that own Celgene stock include Corp /De/ Celgene, Ernest Mario, Gilla Kaplan, James J Loughlin, Mark J Alles, Michael A Friedman, Michael D Casey, Michael W Bonney, Richard W Barker, Robert J Hugin, Rupert Vessey and Terrie Curran. View Institutional Ownership Trends for Celgene.
Who sold Celgene stock? Who is selling Celgene stock?
Celgene's stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Standard Life Aberdeen plc, American Century Companies Inc., UBS Asset Management Americas Inc., Amundi Pioneer Asset Management Inc., First American Bank, Fred Alger Management Inc. and Lazard Asset Management LLC. Company insiders that have sold Celgene company stock in the last year include Ernest Mario, Gilla Kaplan, James J Loughlin, Michael A Friedman, Michael D Casey, Robert J Hugin, Rupert Vessey and Terrie Curran. View Insider Buying and Selling for Celgene.
Who bought Celgene stock? Who is buying Celgene stock?
Celgene's stock was bought by a variety of institutional investors in the last quarter, including Two Sigma Advisers LP, HealthCor Management L.P., Clearbridge Investments LLC, Arrowstreet Capital Limited Partnership, Two Sigma Investments LP, Redmile Group LLC, Swedbank and Thrivent Financial For Lutherans. Company insiders that have bought Celgene stock in the last two years include Corp /De/ Celgene, Mark J Alles and Michael W Bonney. View Insider Buying and Selling for Celgene.
How do I buy Celgene stock?
Shares of Celgene can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Celgene's stock price today?
One share of Celgene stock can currently be purchased for approximately $95.26.
How big of a company is Celgene?
Celgene has a market capitalization of $71.65 billion and generates $13.00 billion in revenue each year. The biopharmaceutical company earns $2.94 billion in net income (profit) each year or $3.58 on an earnings per share basis. Celgene employs 7,467 workers across the globe.
How can I contact Celgene?
Celgene's mailing address is 86 MORRIS AVENUE, SUMMIT NJ, 07901. The biopharmaceutical company can be reached via phone at 908-673-9000 or via email at [email protected]
MarketBeat Community Rating for Celgene (CELG)MarketBeat's community ratings are surveys of what our community members think about Celgene and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Celgene (NASDAQ:CELG) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||2.60||2.53||2.66||2.77|
|Ratings Breakdown: ||1 Sell Rating(s)|
11 Hold Rating(s)
17 Buy Rating(s)
1 Strong Buy Rating(s)
|1 Sell Rating(s)|
12 Hold Rating(s)
17 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
9 Hold Rating(s)
18 Buy Rating(s)
1 Strong Buy Rating(s)
|1 Sell Rating(s)|
4 Hold Rating(s)
21 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$130.36||$130.14||$139.69||$147.58|
|Price Target Upside: ||38.11% upside||27.94% upside||33.68% upside||15.81% upside|
Celgene (NASDAQ:CELG) Consensus Price Target History
Celgene (NASDAQ:CELG) Analyst Ratings History
(Data available from 2/20/2016 forward)
Celgene (NASDAQ:CELG) Earnings History and Estimates Chart
Celgene (NASDAQ CELG) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|1/25/2018||Q4 2017||$1.78||$1.87||$3.46 billion||$3.48 billion||View||Listen|
|10/26/2017||Q3 2017||$1.87||$1.91||$3.42 billion||$3.29 billion||View||N/A|
|7/27/2017||6/30/2017||$1.61||$1.82||$3.23 billion||$3.27 billion||View||N/A|
|4/27/2017||Q1 2017||$1.47||$1.68||$3.04 billion||$2.96 billion||View||N/A|
|1/26/2017||Q416||$1.59||$1.61||$3.03 billion||$2.98 billion||View||N/A|
|10/27/2016||Q316||$1.31||$1.58||$2.84 billion||$2.98 billion||View||Listen|
|7/28/2016||Q216||$1.39||$1.44||$2.70 billion||$2.74 billion||View||Listen|
|4/28/2016||Q116||$1.29||$1.32||$2.59 billion||$2.51 billion||View||Listen|
|1/28/2016||Q415||$1.22||$1.18||$2.54 billion||$2.54 billion||View||Listen|
|11/5/2015||Q315||$1.09||$1.23||$2.40 billion||$2.33 billion||View||N/A|
|7/23/2015||Q215||$1.08||$1.23||$2.24 billion||$2.28 billion||View||Listen|
|4/30/2015||Q115||$0.93||$0.95||$2.11 billion||$2.08 billion||View||N/A|
|1/29/2015||Q414||$0.88||$0.91||$2.08 billion||$2.09 billion||View||N/A|
|10/23/2014||Q314||$0.82||$0.97||$1.96 billion||$1.96 billion||View||Listen|
|7/24/2014||Q214||$0.77||$0.80||$1.85 billion||$1.87 billion||View||N/A|
|4/24/2014||Q114||$1.65||$1.67||$1.77 billion||$1.71 billion||View||N/A|
|1/30/2014||Q413||$1.54||$1.51||$1.72 billion||$1.76 billion||View||Listen|
|10/24/2013||Q313||$1.54||$1.56||$1.64 billion||$1.67 billion||View||N/A|
|7/25/2013||Q2 2013||$1.44||$1.52||$1.54 billion||$1.56 billion||View||Listen|
|4/25/2013||Q1 2013||$1.35||$1.37||$1.47 billion||$1.43 billion||View||Listen|
|1/24/2013||Q4 2012||$1.31||$1.32||$1.45 billion||$1.42 billion||View||Listen|
Celgene (NASDAQ:CELG) Earnings Estimates
2018 EPS Consensus Estimate: $7.93
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Celgene (NASDAQ:CELG)
No dividend announcements for this company have been tracked by MarketBeat.com
Celgene (NASDAQ CELG) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 0.95%
Institutional Ownership Percentage: 77.84%
Celgene (NASDAQ CELG) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|2/8/2018||Mark J Alles||Insider||Buy||3,260||$91.90||$299,594.00||178,904|| |
|9/25/2017||Terrie Curran||Insider||Sell||1,727||$143.89||$248,498.03||3,925|| |
|9/12/2017||Gilla Kaplan||Director||Sell||9,250||$141.56||$1,309,430.00||85,551|| |
|9/5/2017||Michael D Casey||Director||Sell||9,250||$139.03||$1,286,027.50||9,250|| |
|8/10/2017||Ernest Mario||Director||Sell||18,506||$130.52||$2,415,403.12||69,424|| |
|8/2/2017||Gilla Kaplan||Director||Sell||7,500||$134.52||$1,008,900.00||76,301|| |
|6/26/2017||James J Loughlin||Director||Sell||18,500||$133.57||$2,471,045.00||32,877|| |
|6/22/2017||Michael A Friedman||Director||Sell||10,000||$132.50||$1,325,000.00||5,000|| |
|6/22/2017||Robert J Hugin||Insider||Sell||175,970||$134.14||$23,604,615.80||1,033,909|| |
|6/21/2017||Michael D Casey||Director||Sell||9,250||$133.05||$1,230,712.50||9,250|| |
|6/19/2017||Michael D. Casey||Director||Sell||9,250||$125.59||$1,161,707.50|| |
|6/15/2017||Rupert Vessey||Insider||Sell||4,785||$120.18||$575,061.30||4,004|| |
|5/1/2017||James J Loughlin||Director||Sell||9,250||$124.00||$1,147,000.00||32,169|| |
|3/30/2017||Gilla Kaplan||Director||Sell||14,033||$123.83||$1,737,706.39||73,109|| |
|3/1/2017||Rupert Vessey||Insider||Sell||4,000||$124.42||$497,680.00||778|| |
|11/9/2016||Michael A Friedman||Director||Sell||18,600||$116.10||$2,159,460.00||18,600|| |
|10/24/2016||Corp /De/ Celgene||Major Shareholder||Buy||800,150||$14.00||$11,202,100.00|| |
|10/3/2016||Michael A Friedman||Director||Sell||56,116||$103.66||$5,816,984.56||50,000|| |
|9/23/2016||Richard W Barker||Director||Sell||20,000||$110.82||$2,216,400.00||31,332|| |
|9/15/2016||Gilla Kaplan||Director||Sell||9,710||$106.44||$1,033,532.40||72,142|| |
|8/23/2016||James J Loughlin||Director||Sell||27,500||$114.10||$3,137,750.00||42,919|| |
|8/22/2016||Michael D Casey||Director||Sell||43,134||$114.01||$4,917,707.34|| |
|7/28/2016||Robert J Hugin||Insider||Sell||100,000||$110.00||$11,000,000.00||1,022,201|| |
|6/20/2016||Robert J Hugin||Insider||Sell||75,000||$100.16||$7,512,000.00||1,122,201|| |
|4/4/2016||Gilla Kaplan||Director||Sell||15,967||$101.84||$1,626,079.28||72,518|| |
|3/3/2016||Michael W Bonney||Director||Buy||2,000||$103.01||$206,020.00|| |
|2/22/2016||James J Loughlin||Director||Sell||2,100||$104.12||$218,652.00||19,785|| |
|12/28/2015||Ernest Mario||Director||Sell||40,000||$119.36||$4,774,400.00||82,449|| |
|12/23/2015||Michael D Casey||Director||Sell||20,000||$122.11||$2,442,200.00|| |
|12/21/2015||Gilla Kaplan||Director||Sell||14,464||$110.62||$1,600,007.68||88,485|| |
|9/10/2015||Gilla Kaplan||Director||Sell||15,000||$122.45||$1,836,750.00||88,485|| |
|9/8/2015||Michael D. Casey||Director||Sell||15,000||$121.76||$1,826,400.00|| |
|7/13/2015||Thomas O Daniel||Insider||Sell||30,156||$120.78||$3,642,241.68|| |
|6/10/2015||Gilla Kaplan||Director||Sell||15,000||$111.74||$1,676,100.00|| |
|6/9/2015||Michael D Casey||Director||Sell||15,000||$111.18||$1,667,700.00|| |
|2/26/2015||Gilla Kaplan||Director||Sell||15,000||$122.89||$1,843,350.00|| |
|2/6/2015||Mark J Alles||Insider||Sell||117,099||$120.68||$14,131,507.32|| |
|1/15/2015||Lawrence V Stein||Insider||Sell||26,666||$120.01||$3,200,186.66|| |
|1/2/2015||Gilla Kaplan||Director||Sell||45,536||$113.47||$5,166,969.92|| |
|12/8/2014||Gilla Kaplan||Director||Sell||15,000||$118.20||$1,773,000.00|| |
|11/3/2014||Robert J Hugin||Insider||Sell||158,000||$106.68||$16,855,440.00|| |
|10/27/2014||Ernest Mario||Director||Sell||100,000||$102.85||$10,285,000.00|| |
|10/24/2014||Michael D Casey||Director||Sell||15,000||$102.94||$1,544,100.00|| |
|9/8/2014||Gilla Kaplan||Director||Sell||30,000||$93.73||$2,811,900.00|| |
|8/4/2014||Perry A Karsen||Insider||Sell||39,104||$87.55||$3,423,555.20|| |
|7/25/2014||Richard W Barker||Director||Sell||17,600||$87.03||$1,531,728.00|| |
|5/1/2014||Perry Karsen||Insider||Sell||11,922||$146.78||$1,749,911.16||25,705|| |
|3/4/2014||Michael Casey||Director||Sell||12,770||$162.33||$2,072,954.10|| |
|2/5/2014||Ernest Mario||Director||Sell||13,500||$151.87||$2,050,245.00||100,671|| |
|12/23/2013||Lawrence Stein||Insider||Sell||12,062||$168.19||$2,028,707.78||50|| |
|10/25/2013||Carrie Smith Cox||Director||Sell||18,750||$157.67||$2,956,312.50|| |
|9/4/2013||Gilla Kaplan||Director||Sell||15,000||$143.92||$2,158,800.00||22,688|| |
|8/28/2013||Thomas Daniel||Insider||Sell||32,263||$137.06||$4,421,966.78||15,349|| |
|8/2/2013||Perry A Karsen||Insider||Sell||93,008||$146.50||$13,625,672.00|| |
|5/30/2013||Robert J Hugin||Insider||Sell||68,087||$123.58||$8,414,191.46|| |
|5/29/2013||Ernest Mario||Director||Buy||1,000||$123.72||$123,720.00|| |
|5/28/2013||Thomas O Daniel||Insider||Sell||32,959||$124.91||$4,116,908.69|| |
Celgene (NASDAQ CELG) News Headlines
Celgene (NASDAQ:CELG) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Celgene (NASDAQ:CELG) Income Statement, Balance Sheet and Cash Flow Statement
Celgene (NASDAQ CELG) Stock Chart for Tuesday, February, 20, 2018